Celgene's Revlimid misses in Phase III for follicular lymphoma

Celgene Corp. (NASDAQ:CELG) said Revlimid lenalidomide plus Rituxan rituximab missed the co-primary endpoints of improving complete response/unconfirmed complete response

Read the full 199 word article

User Sign In